Saba Molhemi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Saba Molhemi has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Brian Hansen
Center of Functionally Integrative Neuroscience, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
3 shared publications - Christian Stald Skoven
Center of Functionally Integrative Neuroscience, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
2 shared publications Leif Østergaard
Affiliation Center of Functionally Integrative Neuroscience, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
2 shared publications- Aishat O. Ameen
Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, 2100 Copenhagen, Denmark
1 shared publication - Blanca Irene Aldana
Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences University of Copenhagen Copenhagen Denmark
1 shared publication - Caroline Degel
Affiliation Department of Neuroscience, University of Copenhagen, Copenhagen, Denmark
1 shared publication
Latest Publications
- Open Access
- 14 November 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (11) , e0333627
Isoflurane anesthesia alters 31P magnetic resonance spectroscopy markers compared to awake mouse brain
Normal brain function hinges on energy-intensive processes. Consequently, alterations to the brain’s metabolic state are common hallmarks in several pathological conditions. Phosphorus Magnetic Resonance Spectroscopy ( 31 P MRS) is a noninvasive method for measuring key markers of brain energy metabolism, including adenosine triphosphate (ATP), inorganic phosphate (Pi), and phosphocreatine (PCr), as well as markers for cell membrane phospholipid turnover, phosphomonoester (PME) and phosphodiester (PDE). Preclinical rodent 31 P MRS has so far been done under anesthesia - with isoflurane being one of the most commonly used anesthetic agents. The use of isoflurane in 31 P MRS is a concern, as anesthetics are known to affect neuronal activity and energy metabolism in the brain. Its use therefore comes with a risk of perturbing brain physiology. Awake mouse MRS avoids this and allows the effect of isoflurane to be quantified. Thus, we here compare mouse brain 31 P MRS in awake MR-habituated mice and isoflurane anesthesia. We find that 31 P metabolite levels differ between the awake state and isoflurane anesthesia in mice. Our findings show that low-dose isoflurane anesthesia reduces PCr levels in the mouse brain and is accompanied by decreases in intracellular pH and decreased PME levels.
- 14 November 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (11) , e0333627
Open AccessIsoflurane anesthesia alters 31P magnetic resonance spectroscopy markers compared to awake mouse brain
Normal brain function hinges on energy-intensive processes. Consequently, alterations to the brain’s metabolic state are common hallmarks in several pathological conditions. Phosphorus Magnetic Resonance Spectroscopy ( 31 P MRS) is a noninvasive method for measuring key markers of brain energy metabolism, including adenosine triphosphate (ATP), inorganic phosphate (Pi), and phosphocreatine (PCr), as well as markers for cell membrane phospholipid turnover, phosphomonoester (PME) and phosphodiester (PDE). Preclinical rodent 31 P MRS has so far been done under anesthesia - with isoflurane being one of the most commonly used anesthetic agents. The use of isoflurane in 31 P MRS is a concern, as anesthetics are known to affect neuronal activity and energy metabolism in the brain. Its use therefore comes with a risk of perturbing brain physiology. Awake mouse MRS avoids this and allows the effect of isoflurane to be quantified. Thus, we here compare mouse brain 31 P MRS in awake MR-habituated mice and isoflurane anesthesia. We find that 31 P metabolite levels differ between the awake state and isoflurane anesthesia in mice. Our findings show that low-dose isoflurane anesthesia reduces PCr levels in the mouse brain and is accompanied by decreases in intracellular pH and decreased PME levels.
- Open Access
- 13 October 2024
- Published by MDPI AG in Biomolecules
- Vol. 14 (10) , 1294
Comprehensive Analysis of the 5xFAD Mouse Model of Alzheimer’s Disease Using dMRI, Immunohistochemistry, and Neuronal and Glial Functional Metabolic Mapping
Alzheimer’s disease (AD) is characterized by complex interactions between neuropathological markers, metabolic dysregulation, and structural brain changes. In this study, we utilized a multimodal approach, combining immunohistochemistry, functional metabolic mapping, and microstructure sensitive diffusion MRI (dMRI) to progressively investigate these interactions in the 5xFAD mouse model of AD. Our analysis revealed age-dependent and region-specific accumulation of key AD markers, including amyloid-beta (Aβ), GFAP, and IBA1, with significant differences observed between the hippocampal formation and upper and lower regions of the cortex by 6 months of age. Functional metabolic mapping validated localized disruptions in energy metabolism, with glucose hypometabolism in the hippocampus and impaired astrocytic metabolism in the cortex. Notably, increased cortical glutaminolysis suggested a shift in microglial metabolism, reflecting an adaptive response to neuroinflammatory processes. While dMRI showed no significant microstructural differences between 5xFAD and wild-type controls, the study highlights the importance of metabolic alterations as critical events in AD pathology. These findings emphasize the need for targeted therapeutic strategies addressing specific metabolic disturbances and underscore the potential of integrating advanced imaging with metabolic and molecular analyses to advance our understanding of AD progression.
- 13 October 2024
- Published by MDPI AG in Biomolecules
- Vol. 14 (10) , 1294
Open AccessComprehensive Analysis of the 5xFAD Mouse Model of Alzheimer’s Disease Using dMRI, Immunohistochemistry, and Neuronal and Glial Functional Metabolic Mapping
Alzheimer’s disease (AD) is characterized by complex interactions between neuropathological markers, metabolic dysregulation, and structural brain changes. In this study, we utilized a multimodal approach, combining immunohistochemistry, functional metabolic mapping, and microstructure sensitive diffusion MRI (dMRI) to progressively investigate these interactions in the 5xFAD mouse model of AD. Our analysis revealed age-dependent and region-specific accumulation of key AD markers, including amyloid-beta (Aβ), GFAP, and IBA1, with significant differences observed between the hippocampal formation and upper and lower regions of the cortex by 6 months of age. Functional metabolic mapping validated localized disruptions in energy metabolism, with glucose hypometabolism in the hippocampus and impaired astrocytic metabolism in the cortex. Notably, increased cortical glutaminolysis suggested a shift in microglial metabolism, reflecting an adaptive response to neuroinflammatory processes. While dMRI showed no significant microstructural differences between 5xFAD and wild-type controls, the study highlights the importance of metabolic alterations as critical events in AD pathology. These findings emphasize the need for targeted therapeutic strategies addressing specific metabolic disturbances and underscore the potential of integrating advanced imaging with metabolic and molecular analyses to advance our understanding of AD progression.